Imaging end points for monitoring neuroprotection in Parkinson's disease


  • David J. Brooks MD, DSc, FRCP, FMedSci

    Corresponding author
    1. MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    • Hartnett Professor of Neurology. MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Search for more papers by this author


In this review, the potential role of positron emission tomography and single-photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119